Cyclerion Therapeutics Inc.
13F holders, Q4 2025 (December 31)19holders +2
3new positions
2sold out
$1.27avg. 13F price*
At the end of Q4 2025, 19 institutions reported holding Cyclerion Therapeutics Inc. in their 13F filings, up 2 from Q3 2025. 3 opened new positions and 2 sold out. The largest holders were Siren, L.L.C. ($147K), Geode Capital Management, LLC ($55K) and Two Sigma Investments, LP ($53K).
- Company
- Cyclerion Therapeutics Inc.
- CUSIP
- 23255M204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $59K |
| Exits | 2 | $100K |
All 13F filers, Q3 2025 → Q4 2025: 82,175 shares bought and 44,828 shares sold, net +37,347 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Siren, L.L.C. | 0.00% | Reduce -0.5% | 115,603 | $147K |
| Geode Capital Management, LLC | 0.00% | Add +16.5% | 43,302 | $55K |
| Two Sigma Investments, LP | 0.00% | Add +212.6% | 41,555 | $53K |
| Two Sigma Advisers, LP | 0.00% | New | 28,300 | $36K |
| Vanguard Group Inc. | 0.00% | No change | 23,490 | $30K |
| BlackRock, Inc. | 0.00% | No change | 16,797 | $21K |
| XTX Topco Ltd | 0.00% | New | 10,027 | $13K |
| Citigroup Inc. | 0.00% | New | 8,204 | $10K |
| FMR LLC | 0.00% | Reduce -0.1% | 4,740 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +35.5% | 3,154 | $4K |
| UBS Group AG | 0.00% | Add +667.4% | 376 | $478 |
| Group One Trading LLC | 0.00% | No change | 192 | $244 |
| Osaic Holdings, Inc. | 0.00% | No change | 130 | $165 |
| Bank of America Corp. | 0.00% | Add +386.4% | 107 | $136 |
| MAI Capital Management | 0.00% | No change | 100 | $127 |
| Activest Wealth Management | 0.00% | No change | 100 | $127 |
| WHI TRUST Co LLC | 0.00% | — | 72 | $91 |
| BNP Paribas Financial Markets | 0.00% | No change | 5 | $6 |
| Morgan Stanley | 0.00% | Reduce -99.8% | 1 | $2 |
"% of holder's portfolio" is CYCLERION THERAPEUTICS INC's weight in each manager's 13F, not the share of Cyclerion Therapeutics Inc. the manager owns.